You are here

ASH 2022

45 days later, BioCryst abandons another program, citing stiff competition

Fierce Biotech

Thu, 12/15/22 - 11:07 am

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

EP Vantage

Wed, 12/14/22 - 10:18 am

Nurix Therapeutics

ASH: Novartis stays the course with cell therapy bet as competitors line up 'off-the-shelf' options

Fierce Biotech

Tue, 12/13/22 - 10:36 am

ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca

Fierce Biotech

Tue, 12/13/22 - 10:28 am

ASH 2022 – Orchard gets a Sanfilippo boost

EP Vantage

Tue, 12/13/22 - 10:24 am

Orchard Therapeutics

Sanfillipo Syndrome

ASH: Bristol's 3rd-line Abecma data didn't make the trip to New Orleans. Is it cause for concern?

Fierce Pharma

Mon, 12/12/22 - 10:59 pm

Bristol Myers Squibb

clinical trials

Multiple Myeloma

J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways

BioPharma Dive

Mon, 12/12/22 - 10:56 pm

Multiple Myeloma

ASH: Eli Lilly pads novel BTK's case amid FDA review. But AbbVie-J&J, BeiGene and AZ need not worry

Fierce Biotech

Mon, 12/12/22 - 10:45 pm

Seagen rolls out data for Adcetris combination to treat Hodgkin lymphoma

Endpoints

Mon, 12/12/22 - 10:39 pm

Hodgkin's lymphoma

ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets

Fierce Biotech

Mon, 12/12/22 - 10:33 am

Multiple Myeloma

Bristol Myers Squibb

ASH: Roche records phase 3 rare disease win ahead of Soliris showdown

Fierce Biotech

Mon, 12/12/22 - 10:29 am

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

Fierce Biotech

Mon, 12/12/22 - 10:23 am

Sierra Oncology

ASH: Roche touts Lunsumio's durable efficacy as AbbVie, Regeneron plot lymphoma bispecific battle

Fierce Pharma

Mon, 12/12/22 - 10:21 am

ASH: Bristol Myers bolsters Breyanzi's case in earlier lymphoma amid clash with Gilead

Fierce Pharma

Mon, 12/12/22 - 10:16 am

Bristol Myers Squibb

B-cell lymphoma

ASH: Despite partial clinical hold, bluebird's sickle cell gene therapy remains on track

Fierce Pharma

Sun, 12/11/22 - 01:34 pm

sickle cell disease

ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease

Fierce Pharma

Sun, 12/11/22 - 01:32 pm

Setting the Stage for ASH 2022

BioSpace

Fri, 12/9/22 - 10:50 am

Vega Therapeutics

ASH preview – waiting for Editas

EP Vantage

Wed, 11/9/22 - 10:40 am

sickle cell disease

Sangamo BioSciences

Editas Medicine

Vertex Pharmaceuticals

Ash 2022 preview – Affimed and Aptose score

EP Vantage

Sun, 11/6/22 - 01:24 pm

Aptose Biosciences

Ash 2022 preview – a new multiple myeloma mechanism makes a splash

EP Vantage

Sun, 11/6/22 - 01:23 pm

mutliple myeloma